Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept sequencing with panretinal photocoagulation for diabetic retinopathy
ChiCTR2200060038Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in diabetic retinopathy (DR) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Proportion of participants with >=2-step improvement in ETDRS diabetic retinopathy severity scale. Started May 2022; status: recruiting.
02
Drugs
conbercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR2200060038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060038.